PURPOSE: To evaluate the effects of oral @entity1499 ( @entity6822 ) in @entity1 with @entity989 (CSC). METHODS: This is an interventional, prospective uncontrolled clinical trial, which included 23 eyes of 23 consecutive @entity1 presenting with chronic symptomatic CSC and persistent subretinal fluid (SRF) for longer than 3 months. All @entity1 were treated with 7.5   mg/week of oral @entity6822 for 12 weeks. The best corrected visual acuity (BCVA), @entity1020 ( @entity1020 ), SRF, and total macular volume recorded by monthly optical coherence tomography were analyzed. Complete blood count and serum liver enzymes level were monitored. RESULTS: Mean duration of CSC was 13 months (3-36 months). Mean BCVA improved from 20/40 at baseline to 20/30 at the third month and 20/28 at the sixth month (P=0.002 and 0.003, respectively). Mean @entity1020 decreased from 375    m at baseline to 278    m and 265    m at the third and sixth month (P=0.002 and 0.007, respectively). Mean total macular volume decreased from 9.33   mm(3) at baseline to 8.48 and 8.31   mm(3) at the third and sixth month (P=0.001 and 0.001, respectively). Thirteen (62%) eyes achieved complete resolution of SRF. No @entity6822 -associated @entity137 was detected. CONCLUSION: Low-dose oral @entity6822 may be an alternative therapeutic option for the treatment of chronic CSC. This study paves the way for a randomized clinical trial comparing the effects of @entity6822 treatment with photodynamic therapy or observation.

Treatment of @entity989 with Oral XXXX .

@entity1 :: ('9606', 'Species') :: ['patients'] @entity137 :: ('MESH:D064420', 'Disease') :: ['toxicity'] @entity6822 :: ('D008727', 'Chemical') :: ['MTX'] @entity989 :: ('MESH:D012164', 'Disease') :: ['chronic central serous chorioretinopathy'] @entity1020 :: ('MESH:D008268', 'Disease') :: ['CMT', 'central macular thickness'] @entity1499 :: ('MESH:D008727', 'Chemical') :: ['methotrexate']
@entity1499 :: (MESH:D008727,Chemical) :: ['Methotrexate']
